Acceptance based on objective response rate data from the Phase 2 LITESPARK-015 trial evaluating WELIREG in certain patients with advanced PPGL If approved, WELIREG would be the only available therapy ...

Merck Research Laboratories, in a press release. “Today’s US filing acceptance demonstrates our commitment to advancing novel therapies, such as Welireg, to help treat patients with certain rare ...

He received his PhD at the University of Cambridge ... Messer, MA, is director of design Analytics at IQVIA’s Applied Data Science Center. With more than 25 years of clinical research and ...

LPO was determined using the MDA Assay Kit (ab118970, Abcam Cambridge, MA, United States) according to the manufacturer ... First of all, this was a single center study and therefore the recruitment ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...

Now, as vice president of information technology of Merck Research Labs, his responsibilities include identifying and implementing new technologies, such as artificial intelligence, that support ...

VP of global clinical development at Merck Research Laboratories, said in a statement. Although the LEAP-015 readout is technically positive given the trial’s dual primary endpoint design ...

HEIDELBERG, Germany, February 06, 2025 / Biotech Newswire / --German independent research institute BioMed X announces the successful completion of its oncology research project in partnership with ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

RAHWAY, N.J., January 28, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with ...